Build A Winning Portfolio With Aviva plc, BAE Systems plc And AstraZeneca plc

Aviva plc (LON: AV), BAE Systems plc (LON: BA) and AstraZeneca plc (LON: AZN) have all the traits of successful long-term investments.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Trying to construct a portfolio that’s built for the long-term, which will help you weather the market’s tantrums, can seem like an impossible task at first.  However, it isn’t really that difficult to construct an all-weather portfolio. All you need to do is invest in a number of large companies trading at attractive valuations, with illustrious histories and stable outlooks.

Aviva (LSE: AV), BAE Systems (LSE: BA) and AstraZeneca (LSE: AZN) are three such companies.

Indeed, Aviva has been around for more than a hundred years and while the company has had some troubles recently it’s well-placed benefit from the UK’s ageing population. BAE is the UK’s premier defence contractor, and, due to the nature of the company’s business, it has few competitors.

Lastly, AstraZeneca has fallen on hard times recently — the company has struggled to replace old products coming off patent with newer treatments, to maintain sales growth. Nonetheless, despite the short-term headwinds facing the company, AstraZeneca has a vast portfolio of drugs under development and these treatments should help return the company to growth when they’re put into production. 

Time to take a look?

So, why should you consider Aviva, BAE and AstraZeneca for your portfolio? 

Well, as mentioned above all three of these companies have specific traits that will help them continue to report steady growth. What’s more, each of these companies has a leading position in the market it operates within — and that can be seen in each company’s equity returns during the past three years. 

For example, Aviva’s shares have returned 28% since the beginning of 2013 (excluding dividends). BAE’s shares have returned 40% (excluding dividends) and AstraZeneca’s have returned 33% (excluding dividends), both  since the beginning of 2013. Over the same period, the FTSE 100 fell 4%, and the FTSE 250 gained 21% (once again both are excluding dividends).

Aviva, BAE and AstraZeneca’s returns since the beginning of 2013 show that these companies can continue to rack up gains for investors even in sluggish markets.

Attractive valuations

The good news is that Aviva, BAE and AstraZeneca are all trading and attractive valuations right now.

Aviva is currently trading at a forward P/E of 9.5. Earnings per share are expected to grow 18% this year and based on this forecast the company is trading at a PEG ratio of 0.5. The shares support a dividend yield of 5.2%.

BAE is currently trading at a forward P/E of 12.8. The company’s earnings per share are expected to fall 3% this year, but pre-tax profit is expected to increase by nearly 50% to £1.5bn. BAE’s shares currently support a dividend yield of 4.2%.

Finally, there’s AstraZeneca, which is currently trading at a forward P/E of 14.3, making it the most expensive company in this article. Earnings per share are expected to fall by 8% this year, remain constant during 2017 and then begin to expand again during 2018. In other words, AstraZeneca is a long-term play suitable for the patient investor. The company shares support a dividend yield of 4.8%, and this payout looks safe for the time being — so investors will be paid to wait for Astra’s recovery.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

The Barclays share price has soared 72% in 2024. Is it too late for me to buy?

I'm looking for a bank stock to buy in early 2025. The 2024 Barclays share price rise has made the…

Read more »

Investing Articles

2 lessons from the HSBC share price soaring 159% in four years

Christopher Ruane looks at the incredible performance of the HSBC share price in recent years and learns some lessons for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

After a 2,342% rise, could this FTSE 250 stock keep going?

This FTSE 250 stock boasts a highly cash-generative business model and has been flying for years. Is it time to…

Read more »

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

2 dividend-paying FTSE shares that could benefit from the AI revolution

Our writer examines two dividend-paying FTSE shares and explains some of the opportunities and risks he sees in their exposure…

Read more »